

Pembrolizumab KEYNOTE-394

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Not qualified for an ESMO-MCBS credit



Serious and disabling adverse effects



Other adjustments



Pembrolizumab KEYNOTE-394

SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response



Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Gastrointestinal Cancers

Therapeutic Indication: For the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD- 1/PD-L1-containing regimen

Experimental Arm: Pembrolizumab

Control Arm: Placebo



